Lawson Macartney, Ph.D., DVM, has been appointed president and chief executive officer of Ambrx, and a member of the board of directors. Dr. Macartney has more than 20 years of experience in the pharma industry. Most recently, he served as senior vice president and head of the emerging business unit at Shire Pharmaceuticals, where he contributed to growing and diversifying the clinical pipeline.
Prior to joining Shire in 2011, Mr. Macartney was senior vice president of global product strategy and project/portfolio management for GlaxoSmithKline, where he spent four years overseeing the commercial evaluation and commercial strategy for assets at all stages of development and identifying in-licensing opportunities. He held additional positions at GlaxoSmithKline, Astra Pharmaceuticals and Ribozyme Pharmaceuticals.
"We are excited to have Lawson lead Ambrx as our pipeline of therapeutics, including our drug conjugates, continues to grow and mature," said John Diekman, Ph.D., chairman of Ambrx's board of directors. "Ambrx has demonstrated the strength of its technology base and pipeline through data and collaborations, and now we believe Lawson's expertise positions him to lead the company in the next stage of its growth."